Lignosus Rhinoceros TM02® as a Complementary Therapy for Uncontrolled Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The goal of this clinical trial is to learn if TM02® works to treat partially controlled or uncontrolled asthma in adults. It will also learn about the efficacy and safety of TM02®. The main questions it aims to answer are: Does TM02® causes bronchodilation (to what extent), improves asthma control, and reduces airway inflammation and blood eosinophils and serum immunoglobulin E levels. Participants will: Take TM02® every day for 90 days. Visit the clinic once every 30 days for checkups, tests and to fill up questionnaires. Keep a diary of their symptoms and the number of times they use a rescue inhaler.
Epistemonikos ID: 07fe0827e9d4911f3fb5b5258eadd6ccfe7a275a
First added on: Jul 01, 2024